116 related articles for article (PubMed ID: 37678622)
21. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
22. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
23. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
24. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?
Epperla N; Vaughn JL; Othus M; Hallack A; Costa LJ
Cancer Med; 2020 Aug; 9(15):5519-5525. PubMed ID: 32558356
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
[No Abstract] [Full Text] [Related]
26. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.
Frata P; Buglione M; Grisanti S; Bonetti B; Vitali E; De Stefani A; Magri E; Peveri A; Marini G; Rossi G; Magrini SM
Tumori; 2005; 91(6):456-62. PubMed ID: 16457141
[TBL] [Abstract][Full Text] [Related]
27. Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.
Ge J; Xia Y; Sun Z; Zhang L; Li X; Li L; Wang X; Zhang X; Li Z; Nan F; Wan W; Xu D; Ding J; Fu X; Zhang M
Leuk Lymphoma; 2022 Jun; 63(6):1369-1374. PubMed ID: 34989286
[TBL] [Abstract][Full Text] [Related]
28. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
Stephens DM; Li H; LeBlanc ML; Puvvada SD; Persky D; Friedberg JW; Smith SM
J Clin Oncol; 2016 Sep; 34(25):2997-3004. PubMed ID: 27382104
[TBL] [Abstract][Full Text] [Related]
29. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
30. The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
Cassidy RJ; Jegadeesh N; Switchenko J; Danish H; Esiashvili N; Flowers CR; Khan MK
Leuk Lymphoma; 2016 Aug; 57(8):1876-82. PubMed ID: 26759182
[TBL] [Abstract][Full Text] [Related]
31. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
32. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
[No Abstract] [Full Text] [Related]
33. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.
Hu S; Song Y; Sun X; Su L; Zhang W; Jia J; Bai O; Yang S; Liang R; Li X; Zhang H; Gao Y; Zhang W; Xiao X; Bao H; Wang N; Ren H; Cen X; Yang S; Zhao Y; Wang Y; Wang Y; Liu A; Wang J; Shi Y; Yuan M; Li Y; He X
Cancer Sci; 2018 Dec; 109(12):3943-3952. PubMed ID: 30302857
[TBL] [Abstract][Full Text] [Related]
34. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
35. Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.
Fluge Ø; Mannsåker B; Torp A; Mjaaland I; Helgeland L; Klos J; Mella O; Berentsen S; Meyer P
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):125-135.e3. PubMed ID: 29352718
[TBL] [Abstract][Full Text] [Related]
36. Combined modality treatment: Outcome in patients with Hodgkin's lymphoma.
Yadav BS; Sharma SC; Malhotra P; Prakash G
J Cancer Res Ther; 2020; 16(1):1-6. PubMed ID: 32362601
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
39. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018.
Durmaz M; Visser O; Posthuma EFM; Brouwer RE; Issa DE; de Jong D; Lam KH; Blijlevens NMA; Zijlstra JM; Chamuleau MED; Lugtenburg PJ; Kersten MJ; Dinmohamed AG
Blood Cancer J; 2022 Mar; 12(3):38. PubMed ID: 35264598
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant radiotherapy and chemotherapy in early-stage diffuse large B cell lymphoma of head and neck with extranodal involvement.
Peng C; Ho J; Bai HX; Huang Y; Huang RY; Yang L
Hematology; 2019 Dec; 24(1):268-275. PubMed ID: 31793408
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
